newsroom.lilly.comLilly.com | Eli Lilly and Company

Skip to main content Careers Partners Investors Contact Globe Lilly Menu Menu Close Close Company Expand mega menu Expand submenu Left Back Company WHO WE ARE Expand About Lilly Key Facts Recognitions LEADERSHIP Expand Governance Executive Committee Board of Directors POLICIES & REPORTS Expand Public Policy Integrated Summary Report Annual Report & Proxy Statement Science Expand mega menu Expand submenu Left Back Science DISCOVERY Expand Clinical Development Pipeline Research & Scientific Discovery Principles of Medical Research Elixir Factor Podcast 100 Years of Insulin DISEASE AREAS Expand COVID-19 Diabetes Cancer Immunology Pain Neurodegeneration CLINICAL RESEARCH Expand Clinical Trials Lilly TrialGuide Expanded Access CSR Synopses PARTNERS Expand Collaborate With Us Scientific Partnering Areas of Interest Office of Alliance Management Chorus R&D Lilly Research Award Program Medicines Expand mega menu Expand submenu Left Back Medicines SAFETY Expand Patient Safety Medication Safety OUR MEDICINES Expand Current Medicines Historic Medicines Suggestions for Patients Manufacturing & Quality RESOURCES Expand Lilly Diabetes Solution Center Lilly Minnesota Insulin Safety Net Program Lilly Oncology Support Center Lilly Pricing Information The Lilly Answers Center Lilly Cares Foundation Impact Expand mega menu Expand submenu Left Back Impact OUR IMPACT Expand Overview Lilly Foundation Lilly Grant Office IMPACT AREAS Expand Increase Access to Medicines Improve Lives and Communities Empower a Diverse Workforce Minimize Our Environmental Impact Operate Ethically and Responsibly TRANSPARENCY Expand Integrated Summary Report ESG Reports News Expand mega menu Expand submenu Left Back News STORIES Expand Caring Science Policy All Stories PRESS RELEASES Expand Recent Archives MEDIA Expand All News Media Kits Media Contacts Social Media Guidelines Search Careers Partners Investors Contact Globe News Stories See all 2021 Updates: Lilly's Global COVID-19 Response View Story Supporting United Way to Meet New Challenges View Story Racial Justice Initiative: Confronting Racial Inequities Head On View Story How Digital and Remote Health Can Help Next-Generation VBAs View Story Meet the Women Behind Our Cancer Research View Story Christalyn Rhodes: Living Her Purpose, Our Purpose View Story Left Previous Prev 1 Next Next Right Press Releases See all Lilly announces additional doses of neutralizing antibody therapy purchased by U.S. government to treat COVID-19 February 26, 2021 Tags | Product INDIANAPOLIS , Feb. 26, 2021 /PRNewswire/ -- The U.S. government has agreed to purchase a minimum of 100,000 doses of bamlanivimab (LY-CoV555) 700 mg and etesevimab (LY-CoV016) 1400 mg together, Eli Lilly and Company (NYSE: LLY) announced. Bamlanivimab and etesevimab together recently received Welldoc and Lilly collaborate to integrate BlueStar® app capabilities into Lilly's connected insulin solutions February 25, 2021 Tags | Product COLUMBIA, Md. and INDIANAPOLIS , Feb. 25, 2021 /PRNewswire/ -- Welldoc, Inc., and Eli Lilly and Company (NYSE: LLY) announced today a collaboration and licensing agreement to integrate Welldoc's software into Lilly 's connected insulin solutions, currently in development. Lilly to Participate in Cowen Health Care Conference February 24, 2021 Tags | Financial INDIANAPOLIS , Feb. 24, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will participate in the Cowen and Company 41 st Annual Health Care Conference on Thursday, March 4, 2021 . Daniel Skovronsky , M.D., Ph.D., Lilly 's Chief Scientific Officer and President of Lilly Research Laboratories Lilly and Rigel Enter Strategic Collaboration to Develop RIPK1 Inhibitors for the Potential Treatment of Immunological and Neurodegenerative Diseases February 18, 2021 Tags | Corporate - Lilly will obtain an exclusive worldwide license to Rigel's RIPK1 inhibitors, including Rigel's Phase 2-ready molecule R552, in all indications - Rigel will receive an upfront cash payment of $125 million, with the potential for up to an additional $835 million in future development, regulatory, Diversity Contact Suppliers Login Terms of Use Privacy Statement Accessibility Statement Sitemap To speak to customer support: Call (800) 545-5979 Copyright © 2021 Lilly. All rights reserved. Twitter Facebook Instagram LinkedIn YouTube Terms of Use Privacy Statement Accessibility Statement Sitemap Lilly...